Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.

Journal of Clinical Psychopharmacology
Yuanhan BaiKeming Gao

Abstract

The aim of the study was to estimate and rank the risk for the discontinuation due to adverse events (DAEs), 7% or more weight gain (WG), and somnolence during the acute and maintenance treatment of bipolar disorder with a mood stabilizer or an antipsychotic monotherapy. The search of MEDLINE, EMBASE, PsycINFO, and clinicaltrials.gov from the inception to December 31, 2018, provided 32 studies in mania, 16 in bipolar depression, and 13 in maintenance. Data of DAEs, WG, and somnolence from each study were extracted. The risk for these variables of an active treatment relative to placebo was estimated with a number needed to harm (NNH) as a single study and pooled sample. For DAEs, pooled NNH ranged from 19 with carbamazepine to -21 with quetiapine-XR in mania, 11 with quetiapine-IR 600 mg/d to -37 with olanzapine/fluoxetine combination in bipolar depression, and 5 with lithium to -8 with asenapine in maintenance. For WG, pooled NNH ranged from 9 with olanzapine to -78 with aripiprazole in mania, 5 with olanzapine to -112 with lithium in bipolar depression, and 4 with olanzapine to 126 with asenapine in maintenance. For somnolence, pooled NNH was from 5 with carbamazepine to 23 with cariprazine in mania, 3 with quetiapine-XR 300 ...Continue Reading

References

May 1, 1997·Annals of Internal Medicine·H J McQuay, R A Moore
Mar 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·David B AllisonDiana D McDonnell
Apr 2, 2003·The American Journal of Psychiatry·Paul E KeckUNKNOWN Ziprasidone in Mania Study Group
Aug 29, 2003·The American Journal of Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Nov 12, 2003·Archives of General Psychiatry·Mauricio TohenAlan Breier
Nov 25, 2003·The Journal of Clinical Psychiatry·Joseph R CalabreseUNKNOWN Lamictal 605 Study Group
Jun 1, 2004·The American Journal of Psychiatry·Robert M A HirschfeldFred Grossman
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Anatoly B SmulevichFred Grossman
Jul 5, 2005·The American Journal of Psychiatry·Joseph R CalabreseJamie Mullen
Jul 14, 2005·Journal of Clinical Psychopharmacology·Steven G PotkinPatricia English
Sep 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sumant KhannaMichelle Kramer
Sep 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Roger S McIntyreJamie Mullen
May 4, 2006·The Journal of Clinical Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Nov 17, 2006·The Journal of Clinical Psychiatry·Charles L BowdenUNKNOWN Depakote ER Mania Study Group
Nov 18, 2006·Journal of Clinical Psychopharmacology·Michael E ThaseUNKNOWN BOLDER II Study Group
Oct 27, 2007·The Journal of Clinical Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Jan 22, 2008·Journal of Clinical Psychopharmacology·Michael E ThaseRandall Owen
Jan 29, 2008·Current Psychiatry Reports·Andrea Fagiolini, K N Roy Chengappa
May 24, 2008·Acta Psychiatrica Scandinavica·C TorrentE Vieta
Jan 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Allan H YoungRaymond Sanchez
Feb 4, 2010·The Journal of Clinical Psychiatry·Susan L McElroyUNKNOWN EMBOLDEN II (Trial D1447C00134) Investigators
Feb 4, 2010·The Journal of Clinical Psychiatry·Allan H YoungUNKNOWN EMBOLDEN I (Trial 001) Investigators
Mar 17, 2010·Biological Psychiatry·Jorge A QuirozVivek Kusumakar
Apr 7, 2010·The Journal of Clinical Psychiatry·Robert M A HirschfeldMichelle Collins
Aug 24, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rif S El MallakhRobert McQuade
Jul 8, 2011·The International Journal of Neuropsychopharmacology·Eduard VietaBjörn Paulsson
Sep 24, 2011·Journal of Psychopharmacology·Jürgen De FruytStephan Claes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here